BioCentury
ARTICLE | Emerging Company Profile

KSQ: Widescreen CRISPR

How KSQ is using its CRISPRomics technology to identify cancer targets

December 20, 2018 10:24 PM UTC

KSQ Therapeutics Inc. is developing therapies using its CRISPRomics technology to identify cancer and immuno-oncology targets by screening all human genes in cancer cell lines and T cells.

The company emerged from stealth in 2017 with a $76 million round led by Flagship Pioneering, with participation from fellow founding investor Polaris Partners, and a leadership team that includes Genzyme veteran David Meeker as president and CEO; Frank Stegmeier, former head of global oncology target discovery at the Novartis Institutes for BioMedical Research, as CSO; and MIT professor David Sabatini as scientific co-founder. ...

BCIQ Company Profiles

KSQ Therapeutics Inc.